The below table is a good overview other investors may find useful (source: Perplexity AI)
Tryptamine Therapeutics stands out due to its innovative IV-infused formulation, which offers significant advantages over traditional oral psilocybin treatments. However, competitors like Compass Pathways are more advanced in clinical development, particularly with their ongoing Phase 3 trials. Though I think any success with competing Ph3 trials is an overall win for the industry and should actually de-risk TYP.
Add to My Watchlist
What is My Watchlist?
